NCT02338245 - Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior Trastuzumab | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

December 29, 2014

Primary Completion Date

May 19, 2016

Study Completion Date

August 25, 2016

Conditions

Metastatic Breast Cancer

Interventions

DRUG

ASLAN001

ASLAN001 400mg BID

DRUG

Lapatinib

Lapatinib 1250mg QD

DRUG

Capecitabine

Capecitabine 1000mg/kg BID days 1-14 of a 21-day cycle

Trial Locations (19)

112

Taiwan, Taipei

114

Taiwan, Taipei

333

Taiwan, Linkou District

833

Taiwan, Kaohsiung City

3143

New Zealand, Tauranga

6000

Australia, Western Australia

8140

New Zealand, Christchurch

10449

Taiwan, Taipei

10507

Taiwan, Taipei

40447

Taiwan, Taichung

119074

Singapore, Singapore

169610

Singapore, Singapore

Unknown

Hong Kong, Hong Kong

Philippines, Bacolod City

Philippines, Dasmariñas

110-744

South Korea, Seoul

135-710

South Korea, Seoul

137-701

South Korea, Seoul

138-736

South Korea, Seoul